Chk
Les inhibiteurs des kinases de point de contrôle (Chk) ciblent les kinases Chk1 et Chk2, qui sont des régulateurs clés de la réponse aux dommages de l'ADN et des points de contrôle du cycle cellulaire. Ces kinases arrêtent la progression du cycle cellulaire en réponse aux dommages de l'ADN, permettant ainsi le temps nécessaire à la réparation. Inhiber les kinases Chk peut empêcher l'arrêt du cycle cellulaire, forçant les cellules endommagées à poursuivre le cycle et à subir finalement l'apoptose. Les inhibiteurs de Chk sont particulièrement précieux dans la recherche sur le cancer, où ils peuvent sensibiliser les cellules tumorales aux agents endommageant l'ADN. Chez CymitQuimica, nous offrons une variété d'inhibiteurs de Chk de haute qualité pour soutenir vos recherches sur la réponse aux dommages de l'ADN, la régulation du cycle cellulaire et l'oncologie.
51 produits trouvés pour "Chk".
Filtrer par
Pourcentage de pureté
0
100
|
0
|
50
|
90
|
95
|
100
- Tri par prix ascendant
- Tri par prix descendant
- Puretés inférieures
- Puretés supérieures
- Livraison estimée la plus rapide
CHK1-IN-4 hydrochloride
CHK1-IN-4 hydrochloride is a potent inhibitor of checkpoint kinase 1 (chk1).Formule :C18H19BrClN7O2Degré de pureté :99.29%Couleur et forme :SolidMasse moléculaire :480.75Monalizumab
CAS :Monalizumab, a humanized antibody, enhances NK cell function by inhibiting NKG2A; used in HNSCC studies.Degré de pureté :95% - >95.0% (SDS-PAGE); 100% (SEC-HPLC)Couleur et forme :Transparent LiquidMasse moléculaire :147 kDa (Predicted)MU-380
CAS :MU-380 is an effective and selective inhibitor of CHK1.Formule :C15H15BrF3N7Couleur et forme :SolidMasse moléculaire :430.23CHK1-IN-12
CHK1-IN-12 (Compound example 1-5) is a highly selective and orally active checkpoint kinase 1 (CHK1) inhibitor, demonstrating an in vitro enzyme IC50 of ≤10 nM and a cellular IC50 of ≤50 nM. This compound suppresses the phosphorylation activity of CHK1 kinase, disrupts DNA damage response pathways, and induces tumor cell cycle arrest and apoptosis. CHK1-IN-12 shows promise for cancer research applications.Formule :C19H19N7O2Couleur et forme :SolidMasse moléculaire :377.16002Chk1-IN-6
CAS :Chk1-IN-6 is a potent, selective, and orally bioavailable CHK1 inhibitor candidate.Formule :C16H18F3N7Couleur et forme :SolidMasse moléculaire :365.364CHK1-IN-9
CHK1-IN-9 (compound 11) is an orally active CHK1 inhibitor with an IC50 of 0.55 nM. It enhances the effects of DNA-damaging agents on tumor cells and exhibits synergistic anticancer activity with Gemcitabine.Couleur et forme :Odour SolidCHK1-IN-15
CHK1-IN-15 (compound 9a) is an ATP-competitive inhibitor of checkpoint kinase 1 (CHK1), exhibiting a binding rate of 95% at a concentration of 1.0 µM. It also acts as a Chk1 target protein ligand of MA203 and is applicable for tumor-related research.PROTAC Chk1 degrader-1
CAS :Compound PROTAC-2, also known as PROTAC Chk1 degrader-1, is a potent degrader of Chk1, exhibiting a DC50 of 1.33 μM. It is utilized in cancer research [1].Formule :C43H44N14O9Couleur et forme :SolidMasse moléculaire :900.9CBP501 Affinity Peptide
CAS :CBP501 Affinity Peptide, a Chk kinase inhibitor, disrupts G2 arrest triggered by DNA-damaging agents and is utilized in cancer research [1].Formule :C68H119N21O25SCouleur et forme :SolidMasse moléculaire :1662.86FLT3/CHK1 ligand-1
FLT3/CHK1 ligand-1 is a PROTAC target protein ligand used in the synthesis of PROTACs, such as [PROTAC FLT3/CHK1 Degrader-1]. [PROTAC FLT3/CHK1 Degrader-1] functions as a potent FLT3/CHK1 PROTAC degrader with antitumor activity.WAY-230563
CAS :WAY-230563 is a serine/threonine kinase inhibitor that blocks CHK1/CHK2-mediated cell cycle checkpoints, leading to G2/M phase arrest in tumour cellsFormule :C17H12N2O2SDegré de pureté :98.40%Couleur et forme :SolidMasse moléculaire :308.35CCT241533 dihydrochloride
CAS :Potent Chk2 inhibitor with 3 nM IC50, 63-fold more selective over Chk1, affects 84 kinases, reduces DNA damage response and apoptosis in cells.Formule :C23H29Cl2FN4O4Couleur et forme :SolidMasse moléculaire :515.41CCT244747
CAS :CCT244747 is a potent and selective CHK1 inhibitor oral, ATP-competitive, and cytotoxic, abrogating drug-induced S and G2 blockade and inducing apoptosis .Formule :C20H24N8O2Degré de pureté :97.02% - 99.17%Couleur et forme :SolidMasse moléculaire :408.457PD 407824
CAS :PD 407824 is a chemical BMP sensitiser that promotes increased cellular sensitivity to subthreshold amounts of BMP4.PD 407824 is a potent inhibitor of the checkpoint kinases Chk1 and WEE1 (IC50s: 47 and 97 nM, respectively).Formule :C20H12N2O3Degré de pureté :98.02%Couleur et forme :SolidMasse moléculaire :328.32GDC-0575 dihydrochloride
CAS :GDC-0575 dihydrochloride (ARRY-575 dihydrochloride) is a selective, orally active CHK1 inhibitor (IC50: 1.2 nM) that exhibits antitumour effects.Formule :C16H22BrCl2N5OCouleur et forme :SolidMasse moléculaire :451.189LY2880070
CAS :LY2880070 is a new checkpoint kinase 1 (CHK1) inhibitor for cancer therapy.Formule :C19H23N7O2Degré de pureté :99.45% - 99.77%Couleur et forme :White SolidMasse moléculaire :381.4316Baricitinib
CAS :Baricitinib (INCB028050) is an orally JAK1 and JAK2 inhibitor. Baricitinib has anti-inflammatory and anti-tumor activity. Cost-effective and quality-assured.Formule :C16H17N7O2SDegré de pureté :99% - >99.99%Couleur et forme :SolidMasse moléculaire :371.42GDC0575 monohydrochloride
CAS :GDC0575 (ARRY575), a potent Chk1 inhibitor, IC50 1.2nM, disrupts cell cycle arrest, allowing DNA repair before mitosis.Formule :C16H21BrClN5ODegré de pureté :97.85%Couleur et forme :SolidMasse moléculaire :414.728CCT245737
CAS :CCT245737 is an orally active, selective Chk1 inhibitor, and is >1,000-fold selective over CHK2 and CDK1.Cost-effective and quality-assured.Formule :C16H16F3N7ODegré de pureté :98.28% - 99.93%Couleur et forme :SolidMasse moléculaire :379.3397ML367
CAS :ML367 inhibits ATAD5 stabilization with low micromolar activity, serving as a probe molecule.Formule :C19H12F2N4Degré de pureté :99.39%Couleur et forme :SolidMasse moléculaire :334.3222
